Advertisement
Advertisement

ACRS

ACRS logo

Aclaris Therapeutics, Inc.

4.21
USD
Sponsored
-0.04
-0.89%
Apr 21, 12:00 UTC -4
Open

Aclaris Therapeutics, Inc. Profile

About

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.

Info & Links

CEO

Neal Walker

Headquarters

701 LEE ROAD,SUITE 103
WAYNE, PA 19087, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

https://www.aclaristx.com

Auditor

PricewaterhouseCoopers LLP

Share holders

46

Employees

73

Aclaris Therapeutics, Inc. Statistics

Valuation Measures

Market Capitalization2

510.02M

Enterprise Value

490.06M

Enterprise Value/EBITDA(ttm)

-6.45

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

62.87

Price to Book(mrq)

4.77

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

1.01%

Operating Margin(ttm)

-829.58%

Profit Margin(ttm)

-969.15%

Return on Equity(ttm)

-52.04%

Return on Invested Capital(ttm)

-53.55%

Return on Assets(ttm)

-35.91%

Income Statement

Revenue(ttm)

7.83M

Revenue Per Share(ttm)

0.06

Gross Profit(ttm)

542.00K

EBITDA(ttm)3

-75.92M

Net Income Available to Common(ttm)

-64.92M

Diluted EPS(ttm)

-0.53

Share Statistics

Beta (5Y Monthly)

0.67

52-Week Change

269.47%

S&P 500 52-Week Change

37.50%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

120.60M

Dividend Yield

0.00%

Float4

113.84M

% Held by Insiders

5.60%

% Held by Institutions

98.34%

Balance Sheet

Total Cash(mrq)

90.75M

Total Cash Per Share(mrq)

0.75

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.36%

Quick Ratio(mrq)

3.36%

Book Value Per Share(mrq)

0.86

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.38

Free Cash Flow(ytd)

-47.22M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement